Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 102, Issue 8, Pages 988-995Publisher
WILEY
DOI: 10.1002/jso.21753
Keywords
liver metastases; metastatic colorectal cancer; regional liver therapy
Funding
- Sanofi
- Aventis
- Pfizer
- Genentech
Ask authors/readers for more resources
Hepatic metastases are common with colorectal cancer. The primary blood supply to hepatic metastases is the hepatic artery. Regional chemotherapy utilizing the hepatic artery is one treatment option for liver metastases. The advantage of hepatic arterial chemotherapy is that high concentrations of the therapeutic drug are obtained in the liver with minimal systemic toxicity. Recently, systemic chemotherapy regimens have been added to hepatic arterial infusional chemotherapy to treat hepatic metastases. Due to the high response rates in the liver, resection rates are increasing in patients originally thought to have unresectable liver disease. Hepatic arterial chemotherapy has also been used in the adjuvant setting after resection of all liver metastases in order to minimize hepatic recurrences. The role of hepatic arterial infusional therapy in treating hepatic colorectal metastases includes treating patients with both resectable and unresectable metastases in the adjuvant, neoadjuvant, or palliative settings. J. Surg. Oncol. 2010; 102: 988-995. (C) 2010 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available